Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

Adalimumab & Infliximab Remain in Newborns after Delivery

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2016

A recent study showed that, when administered during pregnancy, infliximab takes longer to clear an infant’s system than adalimumab…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAnti-TNFinflammatory bowel diseaseinfliximabpregnancy

How to Deliver Difficult News about Patients' Diagnoses

How to Deliver Difficult News about Patients’ Diagnoses

Karen Appold  |  July 14, 2015

Telling a patient that he or she has been diagnosed with rheumatoid arthritis (RA), ankylosing spondylitis, fibromyalgia or another debilitating, painful and/or chronic condition can be upsetting for a patient to hear and difficult for a rheumatologist to convey. Given this, it’s important to prepare for the appointment. “Take a few minutes beforehand to contemplate…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:chronic conditionDiagnosispatient carephysicianrheumatologist

Prior Authorization Requests Delay or Prevent Delivery of Needed Meds

Richard Quinn  |  March 27, 2015

Rheumatologist denounces common practice as a time-draining impediment to patient care

Filed under:Practice Support Tagged with:Health InsuranceMedicationpatient carePractice Managementprior authorizationrheumatologist

Nanoparticle Medicine Delivery Shows Promise

Kurt Ullman  |  June 13, 2013

Researchers treated mouse model of systemic lupus erythematous with mycophenolic acid delivered via nanoparticle. (posted June 18, 2013)

Filed under:Drug Updates Tagged with:LupusNanoparticleSLE

Electronic Prescribing: The First Step Towards an Integrated Health Delivery System?

Staff  |  February 1, 2009

With the introduction of the 2009 Centers for Medicare and Medicaid Services’ (CMS’s) electronic prescribing incentive program, the door is opening for widespread adoption of health information technology (HIT) within the physician’s practice.

Filed under:From the CollegePractice Support Tagged with:Practice Tips

Arkansas Leads the Nation with Landmark Pharmacy Benefit Manager Reform

Joseph Cantrell, JD  |  June 22, 2025

Signed into law in April, the legislation will ban direct and indirect PBM ownership of pharmacies, effective Jan. 1, 2026. It addresses longstanding concerns about conflicts of interest, market consolidation and patient access created by vertically integrated PBM pharmacy models.

Filed under:Legal UpdatesLegislation & Advocacy Tagged with:pharmacy benefit managers (PBMs)state legislation

My Reflections on Research Cuts

Christina D. Downey, MD  |  June 10, 2025

For decades, the U.S. has served as a beacon to the international scientific community. With drastic cuts to scientific investment proposed and implemented, the U.S. stands to lose not only immigrants considering careers in research, but also homegrown scientists. Christina Downey, MD, reflects on the cuts and invites members to be part of the solution.

Filed under:OpinionProfessional Topics Tagged with:ACR advocacyResearch Funding

Incarcerated Individuals with Rheumatic Conditions

Katherine Terracina, MD, & Prajakta P. Masurkar, PhD  |  June 8, 2025

In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.

Filed under:EthicsGuidance Tagged with:Chronic disease managementethical considerationsEthics Forumhealth disparitieshealthcare policymedication accesspatient advocacyprison healthcaretelemedicine

Case Report: Lupus Nephritis, or a Mimic?

Matthew J. Mandell, DO, FACP, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD  |  May 31, 2025

Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportLupus nephritis supplementparvovirus B19syphilis

ACR Executive Committee Holds Meetings with Heads of FDA, CMS

From the College  |  May 17, 2025

As in past administrations, members of the Executive Committee scheduled meetings with leaders of the Food & Drug Administration and Centers for Medicare & Medicaid Services to discuss ACR policy priorities and agency agendas.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:ACR advocacyCenters for Medicare & Medicaid Services (CMS)U.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 125
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences